204 related articles for article (PubMed ID: 16470786)
1. Crossroads in GDNF therapy for Parkinson's disease.
Sherer TB; Fiske BK; Svendsen CN; Lang AE; Langston JW
Mov Disord; 2006 Feb; 21(2):136-41. PubMed ID: 16470786
[TBL] [Abstract][Full Text] [Related]
2. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?
Lindvall O; Wahlberg LU
Exp Neurol; 2008 Jan; 209(1):82-8. PubMed ID: 17963752
[TBL] [Abstract][Full Text] [Related]
3. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study.
Patel NK; Bunnage M; Plaha P; Svendsen CN; Heywood P; Gill SS
Ann Neurol; 2005 Feb; 57(2):298-302. PubMed ID: 15668979
[TBL] [Abstract][Full Text] [Related]
4. In vivo gene delivery of glial cell line--derived neurotrophic factor for Parkinson's disease.
Kordower JH
Ann Neurol; 2003; 53 Suppl 3():S120-32; discussion S132-4. PubMed ID: 12666104
[TBL] [Abstract][Full Text] [Related]
5. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease.
Gill SS; Patel NK; Hotton GR; O'Sullivan K; McCarter R; Bunnage M; Brooks DJ; Svendsen CN; Heywood P
Nat Med; 2003 May; 9(5):589-95. PubMed ID: 12669033
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietin and GDNF enhance ventral mesencephalic fiber outgrowth and capillary proliferation following neural transplantation in a rodent model of Parkinson's disease.
McLeod M; Hong M; Mukhida K; Sadi D; Ulalia R; Mendez I
Eur J Neurosci; 2006 Jul; 24(2):361-70. PubMed ID: 16903847
[TBL] [Abstract][Full Text] [Related]
7. MRI volumetric and intensity analysis of the cerebellum in Parkinson's disease patients infused with glial-derived neurotrophic factor (GDNF).
Chebrolu H; Slevin JT; Gash DA; Gerhardt GA; Young B; Given CA; Smith CD
Exp Neurol; 2006 Apr; 198(2):450-6. PubMed ID: 16455079
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological activities of glial cell line-derived neurotrophic factor (GDNF): preclinical development and application to the treatment of Parkinson's disease.
Lapchak PA; Gash DM; Collins F; Hilt D; Miller PJ; Araujo DM
Exp Neurol; 1997 Jun; 145(2 Pt 1):309-21. PubMed ID: 9217068
[No Abstract] [Full Text] [Related]
9. [Cell therapy and other neuroregenerative strategies in Parkinson's disease (II)].
Mínguez-Castellanos A; Escamilla-Sevilla F
Rev Neurol; 2005 Dec 1-15; 41(11):684-93. PubMed ID: 16317638
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
11. GDNF therapy for Parkinson's disease.
Hong M; Mukhida K; Mendez I
Expert Rev Neurother; 2008 Jul; 8(7):1125-39. PubMed ID: 18590482
[TBL] [Abstract][Full Text] [Related]
12. Localization of nerve growth factor, neurotrophin-3, and glial cell line-derived neurotrophic factor in nestin-expressing reactive astrocytes in the caudate-putamen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/Bl mice.
Chen LW; Zhang JP; Kwok-Yan Shum D; Chan YS
J Comp Neurol; 2006 Aug; 497(6):898-909. PubMed ID: 16802332
[TBL] [Abstract][Full Text] [Related]
13. Research on Parkinson disease.
Slevin JT; Gerhardt GA; Smith CD; Gash DM; Kryscio R; Young B
J Neurosurg; 2005 Feb; 102(2):401. PubMed ID: 15739575
[No Abstract] [Full Text] [Related]
14. [Growth factors as neuroprotective treatment in Parkinson disease?].
Torp R; Singh PB; Sørensen DR; Dietrichs E; Hirschberg H
Tidsskr Nor Laegeforen; 2006 Mar; 126(7):899-901. PubMed ID: 16554879
[TBL] [Abstract][Full Text] [Related]
15. GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action.
Schober A; Peterziel H; von Bartheld CS; Simon H; Krieglstein K; Unsicker K
Neurobiol Dis; 2007 Feb; 25(2):378-91. PubMed ID: 17141511
[TBL] [Abstract][Full Text] [Related]
16. Stroke and TGF-beta proteins: glial cell line-derived neurotrophic factor and bone morphogenetic protein.
Harvey BK; Hoffer BJ; Wang Y
Pharmacol Ther; 2005 Feb; 105(2):113-25. PubMed ID: 15670622
[TBL] [Abstract][Full Text] [Related]
17. New treatment improves symptoms of Parkinson's disease.
Mayor S
BMJ; 2002 Apr; 324(7344):997. PubMed ID: 11976237
[No Abstract] [Full Text] [Related]
18. Emerging restorative treatments for Parkinson's disease.
Deierborg T; Soulet D; Roybon L; Hall V; Brundin P
Prog Neurobiol; 2008 Aug; 85(4):407-32. PubMed ID: 18586376
[TBL] [Abstract][Full Text] [Related]
19. Effects of GDNF pretreatment on function and survival of transplanted fetal ventral mesencephalic cells in the 6-OHDA rat model of Parkinson's disease.
Andereggen L; Meyer M; Guzman R; Ducray AD; Widmer HR
Brain Res; 2009 Jun; 1276():39-49. PubMed ID: 19389387
[TBL] [Abstract][Full Text] [Related]
20. Intravenous glial-derived neurotrophic factor gene therapy of experimental Parkinson's disease with Trojan horse liposomes and a tyrosine hydroxylase promoter.
Xia CF; Boado RJ; Zhang Y; Chu C; Pardridge WM
J Gene Med; 2008 Mar; 10(3):306-15. PubMed ID: 18085726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
